Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M Read more
Avere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal Read more
Merck KGaA institutes in-office requirement for US research team that could lead to 70 layoffs Read more
